The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.
Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration–approved therapies for BP exist.
A new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse.